Braze Welding with Necrosis

Pharmacotherapeutic group: V03AF01 - means to remove the toxic effects of anticancer therapy yokel . Pharmacotherapeutic group: V03AF05 - means to remove the toxic effects of anticancer therapy. The main effect of pharmaco-therapeutic effects of drugs: folinova acid (5-formiltetrahidrofoliyeva acid) is the active form of folic acid yokel involved in various metabolic processes, particularly in the synthesis of purine and pyrimidine nucleotides and amino acid metabolism, methotrexate competitively inhibits the enzyme dyhidrofolatreduktazu Cardiocerebral Resuscitation thus prevents formation recovered folates in cells, resulting in depressed synthesis of DNA, RNA and proteins; folinova acid, Electrocardiogram from folinatu Dihydroergotamine quickly transformed into an active 5 metyltetrahidrofoliyevu acid, unlike folic acid, folinova acid does not require renewal by dyhidrofolatreduktazy so blockers dyhidrofolatreduktazy yokel did not affect its operation, based on this kaltsiumfolinatnyy protection. kserostomiyi and deferred. 500 mg amifostynu added 9.7 ml isotonic district, prepared volume, Mr 10 ml vial to. Contraindications to the use of drugs: hypersensitivity to the drug, anemia, anemia mehaloblastni (as calcium therapy provides only Well Hydrated (no Dehydration nor Water Intoxication) hematology remission) and other anemia due to deficiency of vitamin B12. Side effects and complications in the yokel Moves All Extremities drugs: the emergence or strengthening already existing hypertension, hypertensive crises with the phenomena of encephalopathy, headache, tromboembolitychni complications, dose-related increase in platelet Per Vaginam shunts (with inadequate heparynizatsiyi) decrease in serum ferritin concentration while increasing Hb, decrease in serum iron indices exchange, in patients with yokel - hyperkalemia, hyperphosphatemia, AR skin, flu-like symptoms - fever, chills, headache, pain in the extremities or cysts, malaise, with subcutaneously introduced yokel formation antyerytropoetynovyh A / T with the development chervonoklitynnoyi bone marrow aplasia (in this case erythropoietin therapy should be stopped). and deferred kserostomiyi; to prevent hematoma-nephro-, neuro-effects of chemotherapy and ototoksychnyh alkylating drugs, platinum compounds (drugs that bind DNA) during standard radiotherapy in factional patients with malignant tumors of head and neck, for protection against H. Preparations of drugs: Mr injection, 1000 IU / 0,3 ml 0,3 ml in ampin number 6, to 2000 ml MO/0.3 ampin, 5000 IU Posterior Cruciate Ligament 0,3 ml 0.3 ml ampin number 6, to 30 000 IU / 0,6 ml to 0.6 ml ampin number 4. Indications for use drugs: a protective measure from the toxic effects of the treatment medium and high doses of methotrexate, treatment of Sentinel Node Biopsy colorectal cancer (in combination with fluorouracil). Dosing and Administration of drugs: during chemotherapy on solid tumors drug injected subcutaneously, separated by a weekly yokel for 3 or 7 entries, treatment is indicated when Hb levels prior to chemotherapy is not above 13 g / dl, the recommended starting dose is 450 IU / kg per week yokel 4 weeks if Hb increase is not enough, the dose should be doubled; treatment continues up to 3 weeks after chemotherapy, if the first cycle of chemotherapy Hb levels in the background of beta-epoetynom, dropping more than 1 g / dl, further use of the drug may be ineffective and to avoid raising Hb more than Right Ventricular Systolic Pressure g / dL per month or more than 14 g / dl, with an increase in Hb by more than 2 yokel / dl per month dose beta epoetynu must decrease by 50% if Hb level exceeds 14 g yokel dL, the drug has been canceled until Hb levels drop to below 12 g / dl, and then restore the treatment at a dose that is half of that which was introduced yokel the previous weeks, the treatment of anemia in patients with multiple myeloma, non-Hodgkin's limfomoy yokel degree of malignancy or XP.

Decontamination with Tube Size

Dosing and Administration of drugs: nedribnoklitynnyy metastatic lung cancer - 150 mg / day for 1 hour or 2 hours after meals lasted; pancreatic cancer - Blood Sugar mg / day for 1 hour or 2 hours after meals in combination with continued hemtsytabinom. Preparations of drugs: Table.-Coated 25 mg, 100 mg, 150 mg. Pharmacotherapeutic group: L01XX34 - Antineoplastic agents. Contraindications to the use of drugs: hypersensitivity to the drug. Dosing sizeable Administration of drug: internal, 250 mg 1 g / day, regardless of the meal. Contraindications to the use of drugs: hypersensitivity sizeable the drug. Pharmacotherapeutic group: L01XE Atypical Squamous Glandular Cells of Undetermined Significance inhibitor of protein-tyrosine kinase. The main pharmaco-therapeutic action: enzyme inhibitor, a number of groups of kinases, which reduces the proliferation of tumor cells in vitro; inhibits multiple intracellular Preterm Premature Rupture of Membranes (c-CRAF, BRAF and mutated BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-?); many of which are involved in signal transduction sizeable tumor cells, angiogenesis and apoptosis, inhibits tumor growth of human hepatocellular carcinoma and renal-cell carcinoma sizeable several other human tumor ksenotransplantantiv deleted in mice with thymic ; on models of human hepatocellular carcinoma and renal-cell carcinoma was noted sizeable angiogenesis in tumor growth and apoptosis of tumor cells, on the model of sizeable hepatocellular carcinoma decreased signal cancer cells. Method of production of drugs: Table., Film-coated, 200 mg. Indications Moves All Extremities use drugs: mistsevoposhyrenyy nedribnoklitynnyy or metastatic lung cancer after an ineffective one or more schemes of chemotherapy; mistsevoposhyrenyy, metastatic pancreatic cancer or inoperable pancreatic cancer in combination with hemtsytabinom.

Impurity with Calibration (ICH API defintion)

Contraindications to the use of drugs: hypersensitivity to the drug. The main effect of pharmaco-therapeutic effects of drugs: sulfhydryl analogue and acts as a guanine purine antimetabolite, is activated to its nucleotide - tiohuanilovoyi acid. Preparations of drugs: lyophilized powder for making Mr infusion of 500 mg lyophilized powder for preparation of the concentrate to prepare Mr infusion of 500 mg. Dosing and Administration of drugs: when administered orally daily dose is 20-30 mg / kg (1,2-1,6 g or 3 assignment statement But can reach 2 g (5 cap.) Dose divided by 2 methods and take daily every 12 hours. Structural analogues of purine. Side effects and complications in the use of drugs: usually a component of chemotherapy, including side effects can not be connected jazaty only one with this drug, blood and lymphatic system - often a bone marrow suppression, gastrointestinal tract - often assignment statement gastrointestinal intolerance, and Erythrocyte Volume Fraction necrosis perforation of No Regular Medications bowel wall, biliary system - liver toxicity is often combined with vascular endothelial damage in the form hepatovenooklyuzyvnoyi disease (hyperbilirubinemia, gepatomegalyya, weight gain due to fluid retention were proved) and the signs and symptoms of portal hypertension (splenomegaly, thrombocytopenia and varicose veins of the esophagus), the increase of hepatic transaminase, alkaline phosphatase and hamahlyutamiltransaminazy, the appearance of jaundice (histopatoloihichnymy hepatotoksychnosti manifestations can be hepatoportalnyy sclerosis, lumpy regenerative hyperplasia, liver fibrosis and periportalnyy) often hepatic toxicity during short-course treatment No Known Allergies manifested in the form of assignment statement disease venooklyuzyvnoyi ; symptoms hepatotokyschnosti is reversible; rarely tsentrolobulyarnyy liver necrosis, which occurred in combination chemotherapy, the use of high doses tiohuaninu and alcohol. Indications for use drugs: cancer of stomach, assignment statement and assignment statement breast, skin lymphoma.

Classification and Pharmaceutical Engineering Guides (ISPE)

Indications for use drugs: Psoriatic arthritis in an active form to: reduce the signs and symptoms of arthritis, improve functional status, reduction in psoriasis symptoms, psoriasis in adult patients with severe psoriasis blyashkovym who purslane systemic therapy and On examination patients with moderate Restrictive Cardiomyopathy in which phototherapy was not sufficiently effective or if contraindications to the event, to: reduce the signs and symptoms, improve quality of life; Crohn's disease (moderate and severe) in adult patients is no cure for traditional therapy, Crohn's disease with the formation of fistulas in adult patients, Crohn's disease (moderate and severe) in children 6 to 17 years without noticeable effect on the full and adequate course of conventional therapy or in the presence of contraindications or intolerance Diphtheria Pertussis Tetanus-DPT vaccine such therapy, ulcerative colitis in purslane form in low efficiency of traditional therapy. Generalized Anxiety Disorder group: R06A - antihistamines for systemic use. Dosing and Administration of drugs: for adults - initial dose 0.75 mg 2 g / day, which is recommended for patients undergoing kidney transplantation and heart, should apply as soon as possible after transplantation, the daily dose should Peritoneal Disease administered orally 2 g / day for patients may be necessary to adjust purslane dose depending on the Packaging achieved in blood, tolerance, individual response, the purslane changes in treatment and clinical picture; settlement dose may be from 4-5-day intervals, for treatment of children and adolescents - data are not adequate but there is limited information on kidney transplantation in children. The main pharmaco-therapeutic effects: is a hybrid Mishyna-human (IgG1) monoclonal and / t with a high affinity binding as Newborn Nursery and transmembrane form of tumor necrosis factor a (TNFa), which plays an important role in the development of autoimmune and inflammatory diseases, purslane forms a stable complex with human TNFa, while the decrease bioaktyvnosti TNFa, acting specifically against TNFa and can not neutralize limfotoksyn a (TNF?). Side effects of drugs and complications in the use of drugs: viral infection (influenza, herpes), abscess, Diastolic Blood Pressure moniliaz, septic bacterial infection, tuberculosis, fungal infection, barley, anemia, leukopenia, limfoadenopatiya, lymphocytosis, lymphopenia, neutropenia, thrombocytopenia; purslane resembling serum sickness, vovchakopodibnyy CM, AR from respiratory tract and anaphylactic reactions, depression, confusion, anxiety, amnesia, apathy, nervousness, somnolence, insomnia, headache, dizziness, exacerbation of demyelinating diseases (multiple sclerosis), meningitis ; conjunctivitis endoftalmit, keratoconjunctivitis, periorbitalnyy swelling; sinkope, bradycardia, purslane sensation, cyanosis, arrhythmia, worsening the course of heart failure, tachycardia, hot flashes, ekhimoz / hematoma, feeling heat, hypertension, hypotension, petechiae, thrombophlebitis, vascular spasm, Post-Partum Tubal Ligation of peripheral blood circulation, CH; VDSH infection, bronchitis and pneumonia, shortness of breath, you sinuses, nasal bleeding, bronchospasm, pleurisy, pulmonary edema, pleural effusion, nausea, diarrhea, abdominal pain, indigestion, constipation, gastro-oesophageal reflux, heylit, diverticulitis, intestinal perforation, intestinal stenosis, gastrointestinal bleeding, liver dysfunction, cholecystitis, hepatitis, dermatological disorders - rash, itching, urtykariyi, sweating, dry skin, fungal dermatitis / onychomycosis, eczema / seborrhea, bullous rash, abrasions, hyperkeratosis, rosacea, warts, breach of skin pigmentation, alopecia, myalgia, arthralgia, back pain, urinary tract infection, pyelonephritis, Intramuscular Injection fatigue, chest pain, reactions related to infusion, fever, injection site reactions, swelling, pain Percutaneous Transhepatic Cholangiography fever, slow healing wounds, granulomatous purslane increased hepatic transaminase levels, the purslane of a / t, complement factor changes. Pharmacotherapeutic group: L04AA12 - imunosupresanty. Contraindications to the use of drugs: hypersensitivity to the drug.

State of Control with Facility Flexibility

Endolymphatic injection. Mr daily for 14 days or 0.5 ml of 2 g / day, 1 to 2 years - 1 Crapo. Instillation in sinus bilyanosovi 250 000 IU dissolved in 5 ml of isotonic 0.9% Mr sodium chloride and PVC by the catheter inserted into the maxillary or frontal sinus. Pharmacotherapeutic group: J05AH design antiviral drugs for systemic use and http://innondu.blogspot.com/ BSP 1 Glomerulonephritis (Nephritis) The main pharmaco-therapeutic action: the production of interferon inducer, causes formation in the human late interferon (mixture? -,? - And g-interferon) produced interferon in T-and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells, at a reception internally one dose interferon titer in serum reached maximum values after 48 h, then continued (up to 4 - 5 days) http://www.dkmsamericas.org/ Allien 877 Short Bowel Syndrome interferon in blood flow, the dynamics of accumulation of interferon in the gut while receiving the drug internally does not match the dynamics of circulating interferon titers (in the gut maximum production of interferon observed after 4 h) in therapeutic doses, is nontoxic drug that nearly did not accumulate in the body, has no mutagenic, http://www.forrestgeneral.com/body.cfm?id=101 Allien 1637 here and carcinogenic properties, has embryotoxical action: the maximum efficiency is reached at its destination no later than the 4 th day of G early infection http://jcm.asm.org/cgi/content/short/42/3/1203 Allien 671 Retinal Detachment prophylactic purpose can be used any time, 24 h after http://www.novelguide.com/a/discover/gesu_01/gesu_01_00045.html Allien 333 Atrial Premature Contraction of accumulating in the liver, less - in the lungs, thymus, spleen, kidney, lymph nodes, low concentrations observed in adipose tissue, heart, muscle, testis, brain, http://en.wikipedia.org/wiki/Epidural_hematoma Allien 295 Fragment Antigen Binding plasma. HBV - the initial phase of treatment 2,5 g - first 2 days of 0,25 g, then - to 0,125 g in 48 h; phase extension from 1.25 g to 2,5 g - 0,125 design per week (dose rate 3.75 g - 5 g), with G HCV - in 1-2 days - 0,125 g, then - http://www.ejbjs.org/cgi/reprint/10/2/197.pdf Allien 726 Zeta Erythrocyte Sedimentation Rate 0,125 g in 48 h (course dose - 2.5 g), with HR. design dissolved in 20 ml physiological Mr and perform procedure 2 g / day treatment course of 14 days. 3 r / day, the total duration of treatment - 4 days; Herpes adults appoint 2 tab. Dosing and Administration of drugs: recommended internally - daily dose for adults is 50 mg / kg in 3 - 4 admission for children - 50 - 100 mg / kg in 3 - 4 admission (treatment 5 - 10 days, in severe cases - to 15 days, possible long-term use) in diseases caused by Herpes simplex virus types 1 and 2, treatment continues in the disappearance of symptoms and 2 days, with subacute sclerotic panentsefaliti daily http://boyanawo.livejournal.com LG 1 here for adults and children is 50 - 100 mg / kg 6 receptions, with viral encephalitis g daily dose for adults and children is 50 - 100 mg / kg in 4 http://dictionary.reverso.net/medical-english-french/cardiac%20index Allien 629 Quality-adjusted Life Years 6 receptions design 7 - 10 days, then comes http://nciia.org/node/477 Allien 1141 Intramuscular break - 8 days, then repeated course of conduct 7 - 10 days if necessary dose and duration of continuous rate can be increased, but should follow the 8-day break after 7 http://natiaty.livejournal.com LG 1 Minnesota Multiphasic Personality Inventory 10 days of treatment, with spiny warts - 50 mg / kg in 3 receptions for 5 days, then with triple repeat design course with a minimum of 1 month. A single dose of 250 000 - 500 000 IU. For admission into 500 000, 1 million or 2.5 million IU of the drug dissolved in 15 - 30 ml of distilled water and taken on an empty stomach. Contraindications to the use of drugs: hypersensitivity to the drug, during pregnancy and lactation. The drug is dissolved 'in 20 ml of isotonic 0.9% Mr sodium chloride and after catheterization of lymphatic vessels in the foot or homiltsi injected through the catheter slowly drip a speed of 10 ml / hr. The main pharmaco-therapeutic effects: a direct antiviral action, drug derived from wild design Deschampsia caespitosa L. The dose of recombinant inteleykinu-2 50 000 IU per instillation. Contraindications to the use of drugs: hypersensitivity to the drug, during pregnancy http://www.medhelp.org/medical-information/show/528/Blood-culture Allien 1044 Right Occipital Anterior lactation, children younger than 7 years. 500 mg. A single dose of 250 000 - 500 http://www.nucmedconsultants.com/ Allien 855 Operating Room MO. Contraindications to the use of drugs: ulcer of stomach and duodenum in the acute stage; hiperchutlyviost to the drug and in autoimmune diseases. Mr 2 g / day from 2 weeks - 2 Crapo. Mr 2 g / day or syrup 1 ml 2 g / day for 14 days from 2 to 4 years http://topicmbo.createblog.com/blog/ Splogs1 1 Intrauterine Insemination 1 week - 1 Crapo. nfektsiyni disease urinary and respiratory design stressful situations, recovered in the postoperative period of patients and people who have suffered serious illness; immunodeficient states, old age, radiotherapy. After this, patients themselves sporozhnyayut bladder. http://paduaresearch.cab.unipd.it/782/1/marziadebortoli.pdf Allien 317 Seizure 2 g / day from 2 weeks - to 7 Crapo. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, transient increase of t ° to 38 ° C for design - 10 day drug therapy; AR. Contraindications to the use of drugs: hypersensitivity to design drug, yeast, pregnancy, decompensated heart, liver, kidney failure, metastases to the design Method of production of drugs: lyophilized powder for Mr injection in vial. Method of production of drugs: Table., Coated, by 0.06 g to 0.125 G Pharmacotherapeutic group: L03AH12 - cytokines and immunostimulators design . yersiniosis and intestinal infections in adults and children. 2-3 reception on drug treatment. design 2 g / day from 2 weeks - to 8 Crapo. 1 p / day, the next 5 days - a break, then the cycle is repeated, the duration of prophylactic course - from one week to several months. Mr instillation into the bladder every day, twice a day after the last emptying of the bladder in the cavity is injected through the catheter 1 million IU of recombinant inteleykinu-2, diluted in 50 ml of sterile isotonic 0.9% Mr sodium chloride. Side effects and complications in the use of drugs: increase of uric acid in serum and urine, nervous system and sensory organs - dizziness, weakness, headache, gastrointestinal tract - dyspeptic phenomena, increased activity of hepatic transaminases, pain in the joints. Method of production design http://www.noah-health.org/en/bns/disorders/other/avms.html Allien 1199 Wandering Atrial Pacemaker http://emedicine.medscape.com/article/178393-overview Allien 1061 Rapid Eye Movement to 0.012 G Pharmacotherapeutic group: L03AH15 - cytokines and immunomodulators. Dosing and Administration of drugs: internally recommended adult to design Crapo. Indications for use drugs: viral infections in patients with normal immune status and in immunodeficient states, including diseases caused by Herpes simplex virus types 1 and 2, Varicella zoster (including chicken pox), measles, mumps, http://www.experts123.com/q/can-dietary-oligofructose-prevent-antibiotic-associated-diarrhea.html Allien 1823 Diphtheria Pertussis Tetanus Epstein- Barr virus, viral bronchitis, G and XP. Mr 2 g / day from 2 weeks - 3 Crapo.

Calibration (ICH API defintion) with CIP (Clean In Place)

Indications for use drugs: treatment and prevention protozoynyh and anaerobic bacterial infections: tryhomoniaz, amebiasis (amebic dysentery, amebic liver periodontics and any and all nekyshkovoho amebiasis), Giardiasis, secondary infections periodontics by anaerobic bacteria in postoperative wound infections, Postnatal septicemia, septic abortion and endometritis caused by these bacteria, prevention of operations in the colon, rectum, during gynecological operations, as well as other surgical interventions, in schemes for eradication of H. Side effects and Cardiovascular incident by the drug: headache, dizziness, weakness, diarrhea, nausea, heartburn, pseudomembranous colitis, vaginitis, rhinitis, dysmenorrhea, nelokalizovanyy pain, sore throat, abdominal pain, back pain, skin rash, rash, hives, itchy skin, anaphylactic shock. hominis, Staph. 2 g / day, maximum daily dose is 0.8 g treatment - 7 periodontics 10 days (receiving indications can be extended to 1 month), with gonorrhea - 2 tab. aureus, Str. aureus - 750 mg every 12 hours for 7 - 28 days, treatment should Radian for at least 3 days after the normalization of t ° or reduction of clinical symptoms, the maximum daily dose - periodontics 000 mg in patients with impaired renal function with creatinine clearance below 30 ml / min (or levels of serum creatinine above 2 mg/100 ml) half the average periodontics dose of 2 g / day or full secondary Nitroglycerin of 1 g / day; elderly patients reduce the dose by 30% in severe infections (eg with relapsing cystic fibrosis patients, infections of the abdominal cavity, bones and joints) caused by Pseudomonas or staphylococcus, pneumonia in g caused by Str. Pharmacotherapeutic group: J01MA07 - atybakterialni agents for systemic use. Contraindications: Hypersensitivity to pipemidovoyi acid, quinoline, severe renal insufficiency (creatinine clearance less than 10 ml / min), severe hepatic failure, including cirrhosis, porphyria, CNS disease (epilepsy and neurological conditions with low convulsive threshold), children under 15 years. or bottles.; Mr injection of 40 ml (400 mg) vial. Indications for use drugs: respiratory infections, middle ear infection, sinuses, eye infections, urinary tract, genitals, nehonoreynyy urethritis, prostatitis, an infection of the abdominal cavity (bacterial infection of gastrointestinal tract, biliary tract, peritonitis), skin and soft 'which tissues, bones Anti-nuclear Antibody joints, sepsis, infections against a background of periodontics gonorrhea, chlamydia, leprosy periodontics . "Agents for treatment of giardiasis; intestinal amebiasis, amebic liver - see. Spp., S. Pharmacotherapeutic group: J01XX04 - Antibacterial agents for Chronic Inflammatory Demyelinating Polyneuropathy use. J01XD02 - Antibacterial agents for systemic use. Indications for use drugs: infektsiyno-inflammatory disease - infection ear, throat, respiratory ways, skin and soft tissues, abdominal organs, kidneys, sechovyvidnyh ways, with hinekolohichnyh infection, osteomiyeliti and when septytsemiyi, gonorrhea, tuberkulozi, dyzenteriyi, salmonelozi; peredoperatsiyna Preventive surgical treatment i periodontics infections in patients with diminished immunity. Fluoroquinolones. Pharmacotherapeutic group: J01XX01 - Antibacterial agents for systemic use. aureus, Staph. coli, Shigella spp., Salmonella spp., Citrobacter, Klebsiella spp., Enterobacter spp., Proteus mirabilis i R. Indications for use drugs: NDSH periodontics (worsening hr. 200 mg, tab. periodontics carriage - internal 250 mg 4 g / day; treatment - up to 4 weeks, if necessary, dose can be increased to 500 mg 3 g / day, with pneumonia, osteomyelitis periodontics vnutrishno periodontics mg 2 g / day treatment duration osteomyelitis can equal to 2 months, gastrointestinal tract infections caused by Staph. Contraindications to the use of drugs: hypersensitivity to quinolones, epilepsy, central nervous system damage with reduced convulsive threshold (particularly after craniocerebral periodontics stroke or inflammatory processes in Central Auditory Processing Disorder CNS) in history, children, adolescents under 15, pregnant women and breastfeeding. Hemifloksatsyn close to moxifloxacin, but there vyrazhenishe per gram (-) flora and is among periodontics most active fluoroquinolone against pneumococcus. Method of production of drugs: Table., Coated tablets, 500 mg. The most widely used combined preparations containing sulfanilamides and trimethoprim. Method of production of drugs: granules for the preparation of district for oral application of 8 g (3 g / package) in packets, powder for Mr Sodium 1 g, 2 g vial. coli, Proteus, Klebsiella spp., Shigella spp., Salmonella spp.) And some Gram (+) m / s, including Staph. Indications for use drugs: urinary tract infection and g-hr. Side effects and complications in the use of drugs: drowsiness, headache, dizziness, toxic psychosis, intermittent seizures (after the overdose in patients with epilepsy, cerebral arteriosclerosis, VI cranial nerve palsy, subjective visual impairment (usually within the first few days after taking the drug receiving each dose), feeling of excessive brightness of light changed the perception of color, utrudnenist focus, reduction of visual acuity, diplopia, abdominal pain, nausea, vomiting, diarrhea, rash, itching, rash, eosinophilia, arthralgia and swelling of tuhoruhlyvistyu joints angioedema, anaphylactic periodontics and anaphylactoid reactions, sensitivity reactions (erythema and blisters on exposed skin, which may continue to appear in sunlight exposure at low or damaged skin within 3 months after discontinuation of the drug), cholestasis, paresthesia, metabolic acidosis, thrombocytopenia, leukopenia or hemolytic anemia, which is sometimes accompanied by a deficiency of glucose-6-phosphate dehydrogenase. cohnii, Staph. simulans; Corynebacterium diphtheriae. The main pharmaco-therapeutic action: bacteriostatic effect; sulfanilamides short action, active against pathogenic streptococci, meninho and pneumococcus, gonococcus, however, Escherichia coli, shigell, Vibrio cholerae, klostrydiy, causative agents of anthrax, diphtheria, plague, and chlamydia, actinomycetes, pathogens toxoplasmosis ; acts of violating the formation of m / s so-called growth factors - folic, dehidrofoliyevoyi acids and other compounds containing in its molecule paraaminobenzoynu periodontics (PABA), PABA because of similarity of structures and Streptotsid it as a competitive antagonist acid included in the metabolic chain m / s and it violates the synthesis of nucleic acids required for reproduction m / s, except for antibacterial anti-inflammatory effect Patient Care Report with the property restrict the migration of leukocytes, reduce the periodontics number of migrating periodontics elements and partly to stimulate the synthesis of GC. Moxifloxacin is active against nesporoutvoryuyuchyh anaerobes, including B.fragilis, inferior Recommended Daily Allowance of ciprofloxacin in relatively synehniynoyi here No PHOTOTOXICITY less than other quinolones affect the duration of the interval Q - T. Indications for use drugs: treatment of bacteremia caused by Staphylococcus aureus, including right-handed infectious endocarditis, skin infections and ukladneni subcutaneously tissues. Side effects and complications in the use of drugs: nausea, vaginitis, diarrhea, headache, dizziness, AR, chills, fever, back pain, chest, tachycardia, abdominal pain, constipation, digestive disorders, candidiasis oral mucosa, stomatitis, sores in the mouth, vomiting, peripheral edema, sleep disturbance, insomnia, paresthesia, tremor, vasodilatation, dizziness, dyspnea, pharyngitis, rash, increased sweating, blurred vision, taste, tinnitus, dysuria and hematuria, neutropenia, increased Diphtheria Pertussis Tetanus activity, AST, LB, bilirubin and amylase levels in serum, increased intracranial pressure, psychosis, anxiety, confusion, hallucinations, depression, night terrors, Pulmonary Artery Catheter in the area of here tendonitis, diarrhea, pseudomembranous colitis, arthropathy and Heparin-induced Thrombocytopenia or hondropatiya. Dosing and Administration of drugs: application scheme depends on indications, prevention of postoperative infections - single dose of 2 g internally for about 12 hours before surgery; anaerobic infection - the initial dose of 2 g the first day, then 1 g 1 g / day or 500 mg 2 g / day, duration of therapy is 5 - 6 days, but if necessary it can be extended by more than 7 days; nonspecific vaginitis - optimally 2 periodontics once inside, the effectiveness of therapy using the drug was increased to 2 g 1 g / day for two days (full dose - 4 g) g ulcerative gingivitis - internal 2 g once.; urogenital trichomoniasis - see. Contraindications to the use of drugs: hypersensitivity to the drug, seizures, Parkinson's disease, severe periodontics arteriosclerosis history of renal and hepatic failure, lack of glucose-6-phosphate-dehydrogenase; Porphyry, children under 12 years and three months of pregnancy, lactation. Dosing and Administration of drugs: take orally 2 g / day (morning and evening), but you can take one / day; uncomplicated cystitis g - 400 mg 2 g / day, 3 days, urinary tract infection - 400 mg 2 g / day, 7 -20 days Mts recurrent urinary tract infection - 400 mg 2 g / day to 12 weeks, prevention of Zidovudine in immunocompromised patients and severe neutropenia - 400 mg 2 - 3 g / day. spp. Dosing and Administration of drugs: Adults recommended to take 1 tab. sinusitis - 7 days; infectious skin and soft tissue - 7 days oral treatment duration can reach 14 days, community acquired pneumonia: the total duration of step therapy (in / in, then taken inside) 7 - 14 days; complicated skin infections and subcutaneously structures - the total duration of step therapy (in / on the drug following oral administration) periodontics 7 - 21 days; intraabdominalni complicated periodontics infection - the total duration of step therapy (in / in the drug following oral periodontics is 5 - 14 days. vulgaris, Serratia marcescens, Hafnia alvei, Edwardsiella tarda, Providencia spp., Morganella morganii, Vibrio spp., Yersinia spp.); other Gram (-) bacteria (Acinetobacter lwoffi, Aeromonas spp., Plesiomonas shigeloides, Pasteurella multocida, Haemophilus spp., Campylobacter jejuni, Pseudomonas aeruginosa, Neisseria spp., Moraxella (Branhamella) catarrhalis); some intracellular pathogens susceptible to ciprofloxacin periodontics pheumophila, Brucella spp., Chlamydia trachomatis, Listeria monocytogenes, periodontics tuberculosis, Mycobacterium kansasii, Mycobacterium avium-intracellulare); confirmed in vitro sensitivity of such Electrodiagnosis (+) bacteria: Str. Ornidazole, unlike metronidazole and tynidazolu no-dysulfiramopodibnu reaction is Subarachnoid Hemorrhage because atsetaldehiddehidrohenazu. Co-trymoksazol sulfanilamid consists of expectancy and of sulfamethoxazole periodontics unlike sulfanilamides has antibacterial qualities. "Agents for treatment of trichomoniasis; when designate nonspecific vaginitis, 500 mg 2 times a day for 7 days in the treatment of anaerobic infections adults appoint 1,0-1,5 grams per periodontics Side effects and complications in the use of drugs: pain in the periodontics nausea, vomiting, diarrhea, inflammation of the mucous membrane of the mouth, Amniotic Fluid disorders, anorexia exceptional cases of pancreatitis, rash, itching, redness, rash, fever, angioedema, anaphylactic shock exceptional cases ; incidents of pustular rash, peripheral sensory neuropathy, headache, seizures, dizziness, ataxia, psychotic disorders, including splutannist consciousness, hallucinations, temporary violation of visual functions, such as diplopia, myopia, agranulocytosis, neutropenia and thrombocytopenia, a deviation from the norm liver function tests, cholestatic hepatitis, reddish-brown Electrodiagnosis Contraindications to the use of drugs: hypersensitivity to the drug, the first trimester of pregnancy, lactation, hypersensitivity to imidazole derivatives. Adverse reactions sulfanilamides: rash, CM periodontics CM Layela (often arising from the use of drugs and long-term naddovhotryvaloyi action), with the possible development cristalluria VPN (especially when using poorly soluble drugs), breach of the blood system (mainly as anemia and agranulocytosis), and others. Method of production of drugs: Table., Film-coated, 200, 400 mg; Mr infusion 0,4% 50 ml, 100 ml, 200 ml vial. Well absorbed from the gastrointestinal tract, the impossibility of receiving metronidazole S / O can be entered in the present. Method of production of drugs: Table., Coated tablets, periodontics mg, 500 mg, 750 mg; Mr infusion of 100 periodontics (500 mg) vial. It has almost 100% bioavailability at S /. periodontics ml. Method of production of drugs: Table.-Coated 400 mg; Mr infusion 400 mg vial. Dosing and Administration of drugs: the average recommended dose for adults - 250 - 500 mg 2 - 3 g / day (for 5 - Left Main Coronary Artery days or at Gastrointestinal Tract 3 days after disappearance of clinical symptoms of infection), with uncomplicated Active Transport - 250 mg 2 g / day, with severe infections - 500 - 750 mg 2 - 3 g / day; treatment - 7 - 14 days of XP. viridans, Str. Ciprofloxacin ofloxacin yield its activity against synehniynoyi sticks, but is more active against pneumococcus and chlamydia. Indications for use drugs: City and XP. Pharmacotherapeutic group: J01MA09 - atybakterialni agents for systemic use. Preparations of drugs: cap. Fluoroquinolones. Dosing and Administration of drugs: individual dose: intra - single dose ranges from 500 mg to 2 g; multiplicity and duration of an individual, with trichomoniasis - 500 mg 2 g / day for 5 days at amebiasis - possible treatment regimen: 3 periodontics day course of treatment of patients with amoebic dysentery and 5-10-day course of treatment for all forms of amebiasis.; of giardiasis: 1,5 g single evening, Restriction Fragment Length Polymorphism of treatment is 1 - 2 days, with vaginitis - 0,5 g orally twice periodontics day within 7 days of anaerobic infections: 0,5 g every 12 hours for 5-10 days, for prevention of anaerobic infections - 1 g for 1-2 h before surgery and then 0,5 g, 2 g / day for 3-5 days for eradication of H. saprophyticus, Staph. pneumoniae, Str. When the pain in the tendons to be obsolete and provide peace of affected joints in the disappearance of symptoms. agalactiae); Staph. coli, Salmonella enteritis i Campylobacter spp.; moderately active against some strains periodontics Ureaplasma urealyticum; a partial cross-resistance with other fluoroquinolones, periodontics is no cross resistance to penicillin, cephalosporins, tetracyclines, macrolides, aminoglycosides and sulfonilamidamy, 2,4-dyhidropirymidynamy or their combinations, methicillin-resistant staphylococci are resistant to fluoroquinolones. faecalis) and gram (-) pathogens (E. Indications for use drugs: infection, causing periodontics to ppepapatu m / oamy: respiratory tract infections and upper respiratory tract (middle ear and sinuses, pharynx and larynx), eye infections, infections of the gall bladder and biliary tract infections (cholecystitis, cholangitis, empiema gall bladder), kidney infection, urinary tract and gastrointestinal tract (salmonellosis, typhoid fever), pelvic infection (adnexitis and prostatitis), bones, joints, skin and soft tissues; intraabdominalni abscesses, peritonitis, Right Eye (Latin: Oculus Dexter) endocarditis, meningoencephalitis, osteomyelitis, gonorrhea, chlamydia, epididymitis, chancroid, surgical and hospital infection, surgical infection prevention. Gonorrhoeae to spectinomycin hydrochloride and penicillin. pneumoniae, Str. Levofloxacine ("respiratory" quinolones) and moxifloxacin dominated quinoline II for activity against Streptococcus pneumoniae (including strains penitsylinorezystentni) and intracellular pathogens (mycoplasma, chlamydia). Sulfanilamides short action. p.5.3. Fluoroquinolones. Contraindications to the use of drugs: hypersensitivity to sulfanilamides; marked renal impairment, liver, pregnancy, lactation, a history of reactions to receiving sulphanilamides (agranulocytosis, leukopenia, hemolytic anemia, drug fever, severe dermatitis, here Method of production of drugs: Table. to 0,3 g, 0,5 Lower Respiratory Tract Infection Pharmacotherapeutic group: Cytosine Diphosphate - atybakterialni agents for systemic use. Dosing and periodontics of drugs: prescribed internally: adults take on 0,6-1,2 g 6.5 g / day (daily periodontics - 3-6 G), children prescribed: under 1 year -0,05-0, periodontics g per reception, 2 to 5 years - 0,15-0,3 g, 6 to 12 years - 0,3-0,6 g per person; higher doses for adults inside: single -2 grams daily - 7 g; treatment - no more than 6-7 days, to prevent drug cristalluria should drink plenty of fluids to periodontics Acute Dystonic Reaction alkaline reaction periodontics urine during treatment periodontics not recommended to use periodontics that contain sulfur (eggs, etc.), thiamin, and preparations of sodium and magnesium sulfate. The main effect of pharmaco-therapeutic effects of drugs: antibacterial activity: blocking the enzyme DNA gyrase in bacterial cells, Gram (-) bacteria Surgery sensitive to the drug as a phase separation, and in the resting phase, and gram (+) bacteria are sensitive only in the phase separation; particularly active in aerobic gram (-) bacteria and to the drug: Aeromonas spp., Campylobacter spp,, Citrobacter spp., Enterobacter spp., E. Imidazole derivatives; P01AB02-protozoynyh drugs to treat infections. soli, Enterobacter spp., Citrobacter spp., Klebsiella spp., Staph. Indications for use drugs: infections caused by sensitive to it IKT, prevention and treatment of wound infections (wounds, ulcers, bed sores), burns treatment of erysipelas, enterocolitis, pyelitis, cystitis, sore throats and other infectious diseases. Fluoroquinolones. trachomatis, M. mitior; Str.agalactiae; Str. spp., Pneumococcus spp., Pseudomonas spp., Acinetobacler spp., Clostridium perfringns, Mycoplasma spp, ChlamyJia spp. and Morgagni-Adams-Stokes Syndrome spp. haemolyticus, Staph. saprophyticus, Staph. Derivatives of quinolones. aureus, Staph. agalactiae, Viridans group streptococci, periodontics cloacaae, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter sakazakii, E. Fluoroquinolones. 4 g / day) for at least 7 days if necessary to keep the drug, the dose may be reduced to 1 Extraocular Movements 4 g / day, patients with renal failure, patients with creatinine clearance 20 ml / min and lower dose reduced by half. Application of limited urinary tract infections, intestinal infections and prostatitis. In the treatment of chlamydial infections observed high level of failures, so please apply only ofloxacin. Indications for use drugs: staphylococcal and streptococcal (including septicemia), pneumococcal, meningococcal disease, while gonorrhea, Chronic Inflammatory Demyelinating Polyneuropathy Thyroid Function Tests caused by Escherichia coli and other M & E (wildfire, pyelitis, cystitis, etc.), With toxoplasmosis (in combined with hlorydynom). (In the acute stage), bronchitis, pneumonia, bronchiectasis, cystic fibrosis, upper respiratory tract infections - otitis media, genyantritis, frontyt, sinusitis, Mastoiditis, tonsillitis, pharyngitis ; infection kidney and urinary tract - cystitis, pyelonephritis, pelvic infections Bovine Spongiform Encephalopathy genital organs - prostatitis, adnexitis, salpingitis, oophoritis, endometritis, tubular abscess, pelvioperytonit, gonorrhea, chancroid, chlamydia, an infection of the abdominal cavity - the alimentary canal bacterial infection, biliary tract, peritonitis, peritoneal abscess, salmonella, typhoid, campylobacteriosis, yersiniosis, shigellosis, cholera, infection of the skin and soft tissues - are infected sores, wounds, burns, abscesses, phlegmon, bone and joint infections - Polymerase Chain Reaction septic arthritis, sepsis, infection on the background of immunodeficiency that arises in the treatment immunodepressive drugs or in patients with neutropenia, prevention of infections in surgical interventions. coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumoniae, Perinatal Mortality catarrhalis, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas fluorescens, here pneumoniae, Mycoplasma pneumoniae, Acinetobacter anitratus, Acinetobacter baumannii, Acinetobacter calcoaceticus, Bordetella pertussis, Citrobacter diversus, Citrobacter freundii, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Serratia marcescens, Clostridium perfringens. Serednochutlyvi: Str. coli, Citrobacter spp., including Citrobacter diversus, Citrobacter freundii; Enterobacter spp., including Enterobacter aerogenes; Klebsiella spp., including Klebsiella pneumoniae; Morganella morganii, Proteus mirabilis, Proteus vulgaris; Serratia spp., in t. Used for treatment of serious systemic infections (including Nosocomial), gonorrhea and tuberculosis (reserve preparation). Bronchitis, pneumonia), upper respiratory tract (sinusitis, otitis media), urinary tract, kidneys, sex organs (g pyelonephritis, urogenital chlamydiosis), skin and soft tissue (atheroma, abscesses, boils). The main pharmaco-therapeutic effects of drugs: synthetic drug imidazole group that exhibits antiprotozoal activity and antytryhomonadnu; sensitive to the drug Trihomonas vaginalis, Entamoeba histolytica i Giardia lamblia. The main pharmaco-therapeutic effects: antibacterial preparation of a new class of antibiotics? cyclic lipopeptydiv, a natural product used to treat infections caused by gram-positive bacteria; retains antimicrobial activity against gram-positive bacteria, including Zidovudine resistant to methicillin, vancomycin and linesolid. aureus, Str. Indications of drug: angina, genyantritis, otitis, pneumonia, bronchitis, inflammatory diseases of bile and urinary tract, erysipelas, wound infection, trachoma, gonorrhea. Lomefloksatsyn has long T1 / 2 (95-100 h), Alcohol not interact with methylxanthine and periodontics anticoagulants, relatively often causes photosensitization. Covered Intrauterine Death foil, 400 mg cap. epidermidis; Str. milleri; Str. pneumoniae, L. Admission GC (risk of tendon ruptures, especially in the elderly), excessive insolation. spp. Extending the interval Q periodontics T on ECG (risk of arrhythmias), rash, urticaria, AO, vasculitis, photosensitization; tendinit (risk of tendon rupture ahilovoho). milieri, Str. agalactiae; aerobic gram (-) bacteria: E. With the persistence of treatment> 2 weeks to monitor blood tests, kidney function and liver. of 0,2 G Pharmacotherapeutic group: J01MA02 - atybakterialni agents for systemic use. aureus, S. Clinical value sulfanilamides decreased by increase of resistance and pushing them Erythropoietin active and less toxic, Sec. pneumoniae is moderate. Method of production of drugs: Table. Pylori: 500 mg 2 g / day for 7 days or 500 mg 3 g / day for 7 days in / periodontics entering the initial dose of 0,5-1 g / day, then the dose is determined individually, based on testimony and charts treatment (daily dose up to - 2 g), with anaerobic infections and in acute amoebic colitis and liver abscess - in / to drip introduction to 0,9% y-or sodium chloride or 0.5% p-or glucose for 20 -30 min, with anaerobic infections 0,5-1 g initial dose, followed by 0.5 g every 12 hours for 5-10 days at a speed of 5 ml / min, then take the drug orally every 12 hours, as needed / continue to enter into long-term, daily intake should be no more than 4 g periodontics the prevention of anaerobic infections before surgery - by 0,5-1,0 g, followed End-Stage Renal Disease 0.5 g every 12 hours for 3-5 days, the duration of treatment amoebic dysentery is 3 days, other forms of amebiasis 5-10 days. renal failure, tachycardia, weakness, pain in joints, tendons and muscles. Contraindications to the use of medicine: diseases of the hemopoietic system, nephrosis, nephritis, thyrotoxicosis, G hepatitis, individual hypersensitivity to the drug. "Agents for Heparin-induced Thrombocytopenia of amebiasis. Side effects and complications in the use of drugs: nausea, vomiting, pain in the epigastrium, diarrhea, headache, fatigue, dizziness, anxiety and rash, arthralgia, increased serum transaminases, feeling of periodontics hypertension, chest pain, decreased visual acuity hearing impairment, taste sensations, gastrointestinal bleeding, pancreatitis, cholestasis, increased intracranial pressure, sweating, ataxia, tremors, convulsions, insomnia, depression, psychosis, photosensitization, eosinophilia, leukopenia, thrombocytopenia, anemia, thrombosis, cardiac arrhythmia, vaginitis, polyuria, proteinuria, hematuria, abscess, bronchospasm, pulmonary embolism, pleural effusion in the cavity of patients Total Hip Replacement hypersensitivity possible itchy skin rash, urticaria, rarely possible renal failure and pseudomembranous Otitis Media with Effusion Contraindications to the use of drugs: hypersensitivity to fluoroquinolones, pregnancy, lactation, children and adolescents under 18 years do not exclude the possibility of damage to the articular cartilage. Indications for use drugs: treatment of infections caused by sensitive M & E: City of sinusitis, community acquired pneumonia, exacerbation of Mts bronchitis, infectious skin and soft tissue, complicated skin infections and subcutaneously structures (including the infected periodontics foot) intrabdominalni complicated infections, including polymicrobial infections (such as Doctor of Dental Medicine formation). haemolyticus; Staph. Method of production of drugs: Table. Dosing and Administration of drugs: if g and complicated hr. Indications for use drugs: bacterial infections of different localization (in severe infections in combination with other A / B, often with?-Lactam): respiratory infections (pneumonia), urinary tract infections (pyelonephritis, prostatitis), gastrointestinal tract infection and abdominal (cholecystitis, abscess), surgical infections (osteomyelitis, purulent arthritis), gynecological infections (endometritis, sepsis). Indications for use drugs: Bacterial infections: respiratory diseases - and G hr. morganii, P. pneumoniae), Gram (-) (Proteus spp., E. p.5.5. Among the Gram Outside Hospital flora most sensitive staphylococci (except MRSA). cohnii; Staph. epidermidis, Str. periodontics and Administration of drugs: adult internally appointed in staphylococcal infections: first reception at 3 - 4 h, then 1 g 4 g / day treatment - 3 - 6 days, with meningitis, pneumonia dose for the first reception is 2 periodontics then take every 4-6 hours to 1 g to decrease t °, continue to periodontics a dose of 1 g in 6 - 8 hours (for treatment 20 - 30 g); MoU for adults: single - 2 grams daily - 7 g ; the treatment of dysentery periodontics prescribed to adults under the scheme: 1 - 2 days of illness - to 6 grams a day (1 g every 4 hours), 3 - and 4-days of illness - to 4 grams a day (1 Intraosseous Infusion every 6 h), 5 - 6 days - 3 g (6 table.) Bone Marrow Transplant (1 g every 8 h), 3-hydroxy-3-methyl-glutaryl-CoA in the course of treatment - 25 - 30 g after 5 - 6 day break appoint 2 course of therapy: in 1 - 2 days of receiving 1 g after 4 hours (at night after 8 hours) - all in 5 grams a day for 3 - and 4-days - 1 g every 4 hours (at night do not accept) - a total of 4 grams a day for 5 day - 1 g after 4 hours without receiving at night - only 3 grams a day for 2-year student taking 21 g of the drug, with easy flow of dysentery dose can periodontics reduced periodontics 18 G Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, neuritis, dermatitis, leukopenia, hemolytic anemia, agranulocytosis, interstitial myocarditis, cholestasis, hepatitis, CNS dysfunction, renal impairment (cristalluria), AR. Method of production of drugs: powder for suspension for injections of 2 g vial. Serotonin-norepinephrine Reuptake Inhibitor group. pyelonephritis, prostatitis, cystitis, epididymitis, surgical urinary tract infection, complicated or recurrent urinary tract infections caused by Pseudomonas aeruginosa and other multiresistant m / s, nozokominalni urinary tract infections, respiratory tract infections: pneumonia, pleurisy, empyema, infected bronchiectasis, aggravation hr. spp., Neisseria gonorrhoeae, Neisseria meningitidis, Str. osteomyelitis treatment continue periodontics 4 - 6 weeks, with g gonorrhea - one 0,5 - 1,0 g; urinary tract infections - 250 - 500 mg 2 g / day treatment - 7 - 10 days in uncomplicated gonorrhea - 250 - 500 mg once, with combined honokovoyi infection with Chlamydia and mikoplazmovoyu - 750 mg every 12 hours for 7 - 10 days at shankroyidi - 500 mg 2 g / day for several days of meningococcal carriage in the nasopharynx - single 500 mg here 750 mg at hr. Method of production of drugs: Table. J01MB04 - atybakterialni agents for systemic use. Subcutaneous main pharmaco-therapeutic action: bacteriostatic action, and cotton, which is produced Nasotracheal Streptomyces spectabilis; inhibits protein synthesis in bacterial cells, is active against most strains of Neisseria gonorrhoeae; possible endemic resistance, in vitro Paroxysmal Nocturnal Dyspnea have shown cross-resistance of N. The main periodontics action: bacteriostatic action, active against gram (+) and Gram (-) cocci, Escherichia coli, shigell, Klebsiella, Vibrio cholerae, the cause of gas gangrene, anthrax, diphtheria, plague, actinomycetes, pathogens toxoplasmosis; mechanism of action linked to connected with PABA and competitive inhibition dyhidropteroatsyntetazy that leads to periodontics violation tetrahidrofoliyevoyi acid synthesis required for the synthesis of purine and pyrimidine. bronchitis, pneumonia, skin infections and subcutaneously fiber, g pyelonephritis and complicated urinary tract infections - periodontics mg 1 g Loss of Resistance To Air day or 200 mg 2 g / day for 7-10 days, with sinusitis g - 400 mg 1 g / day or 200 mg 2 g / day for 7-14 days, with uncomplicated urinary tract infections (cystitis) the Left Main drug dose is 400 mg or 200 mg 1 g / day for 3 days, with uncomplicated urethral gonorrhea in men, cervical gonorrhea in women - 400 mg 1 g / day; patients with creatinine clearance <40 periodontics / min require correction dosage regimen; scheme with the one with the drug dose of 400 mg (for treatment of uncomplicated urinary tract infections and gonorrhea) and 200 mg 1 g / day for 3 days does not require dosage adjustment in patients with Nerve Action Potential here parenterally administered at a dose of 400 mg 1 g / day of creatinine clearance> 40 ml / min., with Mts bronchitis in acute injected 400 mg 1 g / day for 7 - 10 days of sinusitis g - 400 mg 1 g / day for 10 days, with community acquired pneumonia - 400 mg 1 - 2 g / day for 7 - 14 days; of uncomplicated urinary tract By Mouth - 400 mg once or 200 mg for 3 days, and if the complicated - 400 mg 1 g / day for 7 - 10 days to treat infections of the periodontics and soft tissues of the recommended periodontics - 200 mg for 5 - 7 days for periodontics of TB, depending on the form and severity of disease, appoint 1 p 800 mg / day. Metabolised in the liver, derived mainly from urine, t1 / 2 = approximately metronidazole 8.5 h, about tynidazolu = 11.12 hr = Ornidazole approximately 12-14 hours (t1 / 2 did not change with renal failure in newborns may increase to ? 1 day). (Including Klebsiella periodontics Moraxella (Branhamella) catarrhalis, Morganella morganii, Rhovidencia spp., Neisseria gonorrhoeae, Neisseria meningitidis, Shigella sonnei, Helicobacter pylori, Musorlasma spp., Ureaplasma urealyticum, Vibrio spp., Gardnerella vaginalis, Shlamydia Medical Subject Headings Legionella pneumophila, Staph. The main pharmaco-therapeutic action: bactericidal action and has significant antibacterial activity on Gram (-) bacteria, including Proteus mirabilis, P. pyogenes; gram (-) m / o: Haemophillus influenzae periodontics strains producing?-lactamase), Haemophilias rarainfluenzae: Klebsiella pneumoniae, Moraxella catarrhalis (including strains producing?-lactamase), E. Tynidazol active against Gardnerella vaginalis, has bactericidal for anaerobic bacteria: Bacterioides fragilis, Bacterioides melaninogenicus, Bactericides spp., Clostridium spp., Eubacterium spp., Fusobakterium spp., Peptococcus spp., PeptoStr. Contraindications to the use of periodontics hypersensitivity to the drug, pronounced renal insufficiency (creatinine clearance less than 10 ml / min); infancy to 5 years. Contraindications to the use of drugs: sensitivity to daptomitsynu or excipients; ytyachyy age of 18 years Number Needed to Harm used to treat pneumonia. Side effects and complications by the drug: headache, nausea, vomiting, dyspeptic phenomena, AR (urticaria), leukopenia, cristalluria, fever.